Zobrazeno 1 - 10
of 391
pro vyhledávání: ''
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 143
Introduction Several obstacles may delay receipt of targeted treatment in patients with anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC). This study examined the factors associated with delayed initiation of ALK inhibitor
Autor:
Michael Cabanero, Xuyang Song, Rosalyn A. Juergens, Penelope A. Bradbury, Phillip A. Dennis, John Hilton, P. Brown-Walker, Desiree Hao, John R. Goffin, Sebastien J. Hotte, Anna Tomiak, Gwyn Bebb, Scott A. Laurie, Andrew Robinson, Martin Smoragiewicz, Christian K. Kollmannsberger, I. Gauthier, Moustapha Tehfe, Xiaoqun Sun, Peter M. Ellis, Dongsheng Tu, Paul Wheatley-Price, Mihaela Mates, Janessa Laskin, Glenwood D. Goss, Lesley Seymour, Ming-Sound Tsao
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 143
This multicenter phase Ib study aimed to establish a recommended phase II dose for durvalumab (Du) ± tremelimumab (Tr) in combination with standard platinum-doublet chemotherapy. Eligible patients were enrolled into one of six dose levels (DL) of Du
Autor:
José Hureaux, Christos Chouaid, Anne Marie Chiappa, Mateo Sanchis-Borja, Isabelle Monnet, Jean-Bernard Auliac, Renaud Descourt, Luc Odier, Radj Gervais, Charles Ricordel, Gaelle Jeannin
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 143
Introduction Using immune-checkpoint inhibitors (ICIs) to manage cancer is associated with various immune-related adverse events. Central and/or peripheral neurological disorders are rare and potentially serious. We analyzed the characteristics of no
Autor:
Liron Pantanowitz, Douglas J. Hartman, Humberto E. Trejo Bittar, Jacob A. Jerome, Mitra Mehrad, Sanja Dacic
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 143
Objectives Staging of non-small cell lung carcinoma associated with scar is not discussed in detail in the current American Joint Committee on Cancer staging manual. The recommendation is to include the scar area in the tumor size measurement unless
Autor:
Masato Karayama, Satoshi Goshima, Nobuko Yoshizawa, Hideki Yasui, Hironao Hozumi, Naoki Inui, Yutaro Nakamura, Kazuki Furuhashi, Yasuo Takehara, Takafumi Suda, Tomoyuki Fujisawa, Masataka Sugiyama, Kazutaka Mori, Yuzo Suzuki, Noriyuki Enomoto
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 143
Objectives Conventional evaluation of anti-tumor activity on the basis of tumor size is inadequate for immune checkpoint inhibitors (ICIs). We therefore aimed to assess the usefulness of intravoxel incoherent motion magnetic resonance imaging (IVIM-M
Autor:
Matteo Giaj Levra, V. Grumberg, Anne-Françoise Gaudin, John R. Penrod, Jean-Baptiste Assié, Christos Chouaid, François-Emery Cotté, Ronan Jolivel, B. Jouaneton, C. Calvet, Romain Corre
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 140
Objectives Nivolumab is now a reference treatment for patients with advanced non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy. Little data are available on treatment approaches following discontinuation of nivolum
Autor:
Kaiyan Chen, Xiaoqing Yu, Zhiyu Huang, Yun Fan, Guoping Cheng, Yanjun Xu, Fanrong Zhang, Guanxia Zhu
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 142
The efficacy of immunotherapy in epidermal growth factor receptor (EGFR)-activating non-small cell lung cancer (NSCLC) is limited. However, a series of patients with uncommon EGFR alterations was reported to derive clinical benefit from PD-1 blockade
Autor:
Hui Sun, Chao Zhao, Wei Li, Xiaoxia Chen, Caicun Zhou, Chunyan Wang, Shuo Yang, Fengying Wu, Yayi He, Xuefei Li, Yiwei Liu, Shiqi Mao, Yingying Pan, Shengxiang Ren, Xiaofei Yu, Chunxia Su, Qian Liu, Yan Wang, Anwen Xiong, Guanghui Gao, Bin Chen
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 139
Advanced non-small cell lung cancer (NSCLC) patients harboring non-resistant uncommon epidermal growth factor receptor (EGFR) mutations have stepped into the era of targeted therapy. This study aimed to investigate the incidence of acquired T790M mut
Autor:
Michael Millward, Stephen Clarke, Adrian Lee, Benjamin Solomon, Steven Kao, Malinda Itchins, Thomas John, Kate Burbury, Sarah A. Hayes, Brett G.M. Hughes, Nick Pavlakis, Viive M. Howell, Marliese Alexander, Rachel O'Connell
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 142
Objectives: This study aimed to describe the longitudinal thromboembolism (TE) risk relative to the natural history of disease and clinical course of ROS1 rearranged non-small cell lung cancer (NSCLC). Materials and Methods Cases of ROS1-rearranged N
Autor:
Kentaro Imai, Morihito Okada, Norihiko Ikeda, Yoshihiro Miyata, Hiroyuki Ito, Yasuhiro Tsutani, Masaoki Ito, Haruhiko Nakayama
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 141
Recurrence risk of resected lung adenocarcinoma is represented by pathological stage (pStage), histological subtype, and potentially by EGFR mutation. However, the relationship among these factors and their combined impact on prognosis are unclear.Us